CryoCath at outperform by RBC

CryoCath Technologies Inc. was given an outperform rating, speculative risk, by RBC Capital Markets analyst Phil Nalbone after the company reported 100% positive clinical results in a study of 26 patients who were treated for paroxysmal atrial fibrillation using the Arctic Front. In addition, the company's core business continues to generate a fast-growing revenue stream, according to the analyst, who is predicting full-year sales of $43.4 million and a loss of $18.9 million. Shares of the Montreal-based pharmaceutical company were down 3 cents, or 0.73%, at C$4.07 on volume of 1,645 shares versus the three-month running average of 44,167 shares. (Toronto: CYT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.